Hemophilia without prophylaxis: Assessment of joint range of

Evaluation of CDC's Hemophilia Surveillance Program — Universal Data Collection (1998–2011) and Community Counts (2011–2019), United States

Hemophilia Nursing Care Planning and Management Study Guide - Nurseslabs

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Improvement in Joint Health Observed With Gene Therapy in Hemophilia A - Hematology Advisor

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies - ScienceDirect

Types of prophylaxis therapy in hemophilia and their recommendations

Considerations for shared decision management in previously untreated patients with hemophilia A or B - Jan Astermark, Jan Blatný, Christoph Königs, Cédric Hermans, Victor Jiménez-Yuste, Daniel P. Hart, 2023

PDF) Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity

Frontiers Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A

Algorithm for management of emergency situations in patients with

Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age

Enabling normal psychophysical development in children with hemophilia: the choice for prophylaxis

Severe Hem A Patients Showing Bleeds, Physical Limits With Prophylaxis

COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA, International Journal of Technology Assessment in Health Care